Impact of Phosphodiesterase-5 Inhibitor Treatment Delay on Secondary Raynaud’s Phenomenon Outcomes

Published: 15 January 2026| Version 1 | DOI: 10.17632/tbs4zb2vdv.1
Contributors:
Isabella Zappi, Amit Saxena, Mark Richardson, Chinemelum Obijiofor, Avrom Caplan, Jerry Shapiro, Alisa Femia, Michelle Sikora, Deesha Desai, Ambika Nohria, Kristen Lo Sicco, Daniel Mazori, Derek Maas, Archie Spindler

Description

This dataset includes information collected from patient with secondary Raynaud's phenomenon treated with phosphodiesterase-5 inhibitors. Demographic infromation, secondary Raynaud's phenomenon characteristics, and phosphodiesterase-5 inhibitor effects determined by physician and/or patient reports were collected. Multivariate logistic regression assessed associations with adverse outcomes using RStudio (α=0.05).

Files

Institutions

  • NYU Langone Health

Categories

Rheumatoid Arthritis, Sildenafil, Tadalafil, Connective Tissue, Systemic Lupus Erythematosus, Connective Tissue Disorder, Lupus Erythematosus, Dermatomyositis, Raynaud's Syndrome, Systemic Sclerosis, Phosphodiesterase Inhibitor, Mixed Connective Tissue Disease, Gangrene, Ulcer

Licence